PHARMACEUTICAL COMPANY SANOFI announced today that it will invest €44 million in the Genzyme biotechnology campus in Co Waterford.
More than 500 people are employed at Genzyme Waterford, which produces products for patients living with rare genetic diseases, kidney disease and cholesterol management requirements that are shipped to more than 70 countries around the world.
The investment will increase the site’s range of products by adding the filling of Sanofi’s insulin glargine product which is the number one insulin brand worldwide.
Sanofi acquired Genzyme almost two years ago and the company said today it has been “continually impressed with the record of achievement” at the Waterford site.
Visiting the site today, Minister for Jobs, Enterprise and Innovation, Richard Bruton said this investment, which comes on top of a €150m investment little more than a year ago, will “ensure that this facility can produce the company’s latest product and provides an indication of the Waterford site’s strategic value”.